Skip to main content

Table 5 Multivariable Cox Analysis of predictors for Loco-regional recurrence (LRR), distant metastasis (DM), any progression and overall survival (OS) for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation, (n = 105)

From: The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer

 LRR
HR (95% CI)p-value
RT fractionation2.08 (1.03–4.23)0.04c
Maximum 3D tumor diameter (cm)1.20 (1.10–1.30)< 0.001c
Pack-years1.01 (1.00–1.02)0.10
Concurrent chemotherapy0.24 (0.08–0.69)0.008c
 In-field LRR
HR (95% CI)p-value
Maximum 3D tumor diameter (cm)1.20 (1.01–1.40)0.02c
Tumor Volume1.01 (1.00–1.01)0.03c
Maximum 2D tumor diameter sagittal (cm)0.95 (0.94–1.01)0.08
Maximum 2D tumor diameter axial (cm)0.95 (0.95–1.01)0.08
 DM
HR (95% CI)p-value
T stageb0.58 (0.32–1.05)0.07
Performance status ≥12.54 (1.27–5.09)0.009c
PCI
 Yes0.61 (0.34–1.09)0.10
Pack-years1.01 (1.00–1.02)0.12
Median RT dose1.03 (1.00–1.06)0.09
Maximum 3D tumor diameter (cm)1.10 (1.01–1.10)0.03c
 Any progression
HR (95% CI)p-value
Performance status ≥12.47 (1.31–4.67)0.005c
PCI
 Yes0.57 (0.34–0.95)0.03c
T stageb0.61 (0.35–1.05)0.07
Maximum 3D tumor diameter (cm)1.10 (1.01–1.10)0.01c
 OS
HR (95% CI)p-value
Overall stagea1.09 (0.58–2.07)0.78
T stageb0.53 (0.31–0.90)0.02c
Gender
 Male0.34 (0.20–0.56)< 0.001c
Performance status ≥13.16 (1.71–5.85)< 0.001c
RT fractionation0.58 (0.35–0.97)0.04c
Concurrent chemotherapy0.43 (0.21–0.89)0.02c
Maximum 3D tumor diameter (cm)1.10 (0.99–1.10)0.09
  1. aStage IA-IIIB as referent
  2. bT stage 0–1 as referent; Bolded, italicized values indicate significance, p<0.05
  3. cMeets significance after adjustment for hypothesis testing using a Benjamini-Hochberg FDR of 0.1